Glooko touted data today from a feasibility study evaluating the impact of its mobile insulin dosing system for people with Type II diabetes who are taking long-acting insulin.
The Mountain View, Calif.-based company said it hoped to better understand the extent to which its system can make appropriate insulin titration adjustments and improve a patient’s glycemic status.
After the three-week study, participants’ mean blood glucose levels decreased, on average, by 18.2 mg/dL and the proportion of in-range blood glucose readings increased by 9% on average.
The company also noted that the percentage of hyperglycemic events decreased over the course of the study and that the recommended long-acting insulin dose increased by 18.7%.
“We are thrilled to see early clinical evidence show the positive impact the Glooko mobile insulin dosing system can have on people with diabetes,” CEO Rick Altinger said in prepared remarks.
“Glooko’s mission has always been to improve clinical outcomes for people with diabetes by making diabetes management easier through digital tools. The potential for improving adherence – and thus improving outcomes and reducing costs – can be invaluable to people with diabetes on long-acting insulin globally.”
